HORSHAM, Pa. — February 4, 2025 Ancillare, the global leader in clinical trial supply chain solutions, is excited to announce its new role as a global distributor of the Dexcom G7 Continuous Glucose Monitor (CGM) for clinical trials. This cutting-edge device offers real-time, precise glucose data that will significantly improve study participant compliance, streamline decentralized trials, and reduce errors, making it an invaluable tool for clinical research.
The Dexcom G7 CGM provides accurate, continuous glucose monitoring, allowing healthcare professionals and researchers to access up-to-the-minute insights into participants’ glucose levels. This data enhances study design, increases operational efficiency, and focuses on participant well-being. It ensures that study participants’ glucose numbers are constantly monitored, anytime, anywhere, which is particularly crucial in decentralized and remote trials.
For Sponsors, accuracy and simplicity are paramount. for clinical trials. The Dexcom G7 CGM offers proven accuracy, enabling better -informed treatment decisions. By equipping study participants with this technology, Sponsors can allow participants to manage their diabetes with confidence while optimizing the trial process.
Through Ancillare’s comprehensive clinical trial supply services, Sponsors are supported with significant cost savings, optimize resource allocation, reduce risks, and improve overall coordination throughout the clinical trial supply chain. These capabilities, combined with the advanced technology of the Dexcom G7, ensure a streamlined and efficient clinical trial experience.
For more information about Ancillare and including Dexcom G7 CGM in your clinical trial, visit ancillare.com or contact us.
